Ann: Viraleze shows antiviral efficacy in COVID-19 patients, page-48

Results were not as wonderful as some had hoped.

Nevertheless, a lack of side-effects is confirmed and there is enough meat in the results to expect that commercial success could eventually materialise for Viraleze.

However, this is still SPL. (e.g. The ridiculously long delay while the data was being "cleaned".) My opinion of SPL now? Let's see how SPL follows this up. Acceptance by TGA? FDA? New deals? Substantial revenue? More studies? It seems to still be a gamble. I doubt if SPL has what it takes. But at least it now appears more certain that Viraleze is a product that a more competent pharma could market successfully. So, a takeover becomes a more realistic possibility.